Skip to main content
. 2015 Mar 11;32(11):3526–3540. doi: 10.1007/s11095-015-1657-7
Phase Originator Common name Specificity target Target disease
2 Immunomedics IMMU-130 anti-CEACAM5 CRC
2 Immunomedics IMMU-132 anti-TROP-2 solid tumors